Thermo Fisher Scientific Mouse IL-28A (IFN-lambda 2) Recombinant Protein, PeproTech

Applications

Tested Dilution

Publications

ELISA (ELISA)

-

View 1 publication 1 publication

Functional Assay (Functional)

Assay-dependent

-

In vitro Assay (IV)

-

View 9 publications 9 publications

Miscellaneous PubMed (Misc)

-

View 3 publications 3 publications

Product Specifications

Species

Mouse

Published species

Human, Mouse

Expression System

E. coli

Amino acid sequence

MDPVPRATRL PVEAKDCHIA QFKSLSPKEL QAFKKAKDAI EKRLLEKDMR CSSHLISRAW DLKQLQVQER PKALQAEVAL TLKVWENMTD SALATILGQP LHTLSHIHSQ LQTCTQLQAT AEPKPPSRRL SRWLHRLQEA QSKETPGCLE DSVTSNLFRL LTRDLKCVAS GDQCV

Molecular weight

19.8 kDa

Class

Recombinant

Type

Protein

Purity

≥ 98% by SDS-PAGE gel and HPLC analyses.

Endotoxin concentration

<1 EU/µg

Activity

Determined by its ability to activate STAT following receptor-ligand interaction.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Purification

purified

Contains

no preservative

Storage conditions

-20°C

Shipping conditions

Ambient

Product Specific Information

Recombinant Murine IFN- lambda2 is a 19.8 kDa protein containing 175 amino acid residues.

This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis

Target Information

IL-28A belongs to the IFN lambda family, a novel family of cytokines within the IL-10 superfamily. The three members of this family are IL-29 (IFN lambda 1), IL-28A (IFN lambda 2), and IL-28B (IFN lambda 3), and are also known as the type III Interferons.The IFN lambdas signal through a heterodimeric receptor of which one subunit, IL-10R2, is shared with other members of the superfamily. The second subunit, IFN lambda R1 or IL-28R alpha, is unique to the IFN lambdas. Signaling occurs through the Jak/STAT pathway in a similar manner as the type I IFN (IFN alpha/beta) and activates many of the same genes despite low sequence homology between the cytokines and receptors in the two families. Both IFN families display antiviral activity through the induction of antiviral protein production in target cells and the upregulation of MHC class I expression. These proteins also exhibit antiproliferative and antitumor effects, making them a possible alternative to IFN alpha cancer therapies. Unlike the type I IFN, which are able to stimulate most cells, response to IFN lambda stimulation appears to be limited to dendritic and some tumor cells due to the limited expression of IFN lambda R1. Another notable difference is the ability of the IFN lambda stimulation to drive dendritic cells towards the production of CD4+CD25+FoxP3+ regulatory T cells, suggesting a possible immunoregulatory role

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.